Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Beam Therapeutics (BEAM) Assets Average (2020 - 2025)

Historic Assets Average for Beam Therapeutics (BEAM) over the last 6 years, with Q3 2025 value amounting to $1.4 billion.

  • Beam Therapeutics' Assets Average rose 1108.28% to $1.4 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $1.4 billion, marking a year-over-year increase of 1108.28%. This contributed to the annual value of $1.3 billion for FY2024, which is 849.17% down from last year.
  • Latest data reveals that Beam Therapeutics reported Assets Average of $1.4 billion as of Q3 2025, which was up 1108.28% from $1.4 billion recorded in Q2 2025.
  • Beam Therapeutics' Assets Average's 5-year high stood at $1.5 billion during Q1 2022, with a 5-year trough of $572.5 million in Q1 2021.
  • For the 5-year period, Beam Therapeutics' Assets Average averaged around $1.3 billion, with its median value being $1.3 billion (2023).
  • In the last 5 years, Beam Therapeutics' Assets Average surged by 26043.67% in 2021 and then plummeted by 1727.32% in 2024.
  • Quarter analysis of 5 years shows Beam Therapeutics' Assets Average stood at $1.3 billion in 2021, then grew by 2.32% to $1.3 billion in 2022, then rose by 2.17% to $1.4 billion in 2023, then decreased by 17.27% to $1.1 billion in 2024, then grew by 18.77% to $1.4 billion in 2025.
  • Its Assets Average was $1.4 billion in Q3 2025, compared to $1.4 billion in Q2 2025 and $1.3 billion in Q1 2025.